Valproic acid pathway (WP3871)

Valproic acid is a drug used for treatment and management of seizure disorders, mania and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract and then binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Valproic Acid may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. It is also a histone deacetylase inhibitor. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection. Source: description from http://www.drugbank.ca/drugs/DB00313 Metabolic pathway from: http://smpdb.ca/view/SMP00635 Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP3871 CPTAC Assay Portal].
last edited

Authors

Fehrhart, DeSl, Khanspers, and MaintBot

Cited In

Organism

Homo sapiens

Communities

Diseases

Annotations

Disease Ontology: epilepsy

Pathway Ontology: xenobiotic metabolic pathway valproic acid drug pathway

Cell Type Ontology: neuron hepatocyte

Participants

Label Type Compact Identifier
GABA Metabolite hmdb:HMDB0000112
Pentanoyl-CoA Metabolite hmdb:HMDB0013037
3-Oxovalproic acid Metabolite hmdb:HMDB0060685
ACSM1 GeneProduct ensembl:ENSG00000166743
2-Propylglutaric acid Metabolite hmdb:HMDB0060684
3-Hydroxyvalproic acid Metabolite hmdb:HMDB0013899
2-Propyl-2,4-pentadienoic acid Metabolite hmdb:HMDB0060682
HADHB GeneProduct ensembl:ENSG00000138029
3-ene-Valproic acid CoA Metabolite hmdb:HMDB0060740
4-ene-Valproic acid Metabolite hmdb:HMDB0013897
UGT1A3 GeneProduct ensembl:ENSG00000243135
2-n-Propyl-4-oxopentanoic acid Metabolite hmdb:HMDB0060683
EHHADH GeneProduct ensembl:ENSG00000113790
4-ene-Valproic acid CoA Metabolite hmdb:HMDB0060762
CYP2B6 GeneProduct ensembl:ENSG00000197408
2,3-diene-Valproic acid-CoA Metabolite hmdb:HMDB0060723
Propionyl-CoA Metabolite hmdb:HMDB0001275
4-Hydroxyvalproic acid Metabolite hmdb:HMDB0013900
2,3-diene-Valproic acid-CoA Metabolite hmdb:HMDB0060723
HDAC1 GeneProduct ensembl:ENSG00000116478
HSD17B10 GeneProduct ensembl:ENSG00000072506
3-ene-Valproic acid CoA Metabolite hmdb:HMDB0060740
Uridine 5-diphosphate Metabolite HMDB
3-Hydroxyvalproic acid CoA Metabolite HMDB
3-oxo-Valproic acid CoA Metabolite HMDB
Valproic acid CoA Metabolite HMDB
HADHA GeneProduct Ensembl
2-ene-Valproic acid CoA Metabolite HMDB
5-Hydroxyvalproic acid Metabolite HMDB
CYP2A6 GeneProduct Ensembl
CYP2C9 GeneProduct Ensembl
ACADSB GeneProduct Ensembl
Valproic acid Metabolite HMDB
IVD GeneProduct Ensembl
Uridine diphosphate glucuronic acid Metabolite HMDB
ABAT GeneProduct Ensembl
Valproic acid glucuronide Metabolite HMDB
ACADSB GeneProduct Ensembl
CYP2A6 GeneProduct Ensembl
CYP2B6 GeneProduct Ensembl
CYP2C9 GeneProduct Ensembl
CYP2A6 GeneProduct Ensembl
None

References

  1. Kassahun K, Farrell K, Abbott F. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos. 1991;19(2):525–35. PubMed Europe PMC Scholia
  2. Li J, Norwood DL, Mao LF, Schulz H. Mitochondrial metabolism of valproic acid. Biochemistry. 1991 Jan 15;30(2):388–94. PubMed Europe PMC Scholia
  3. Ito M, Ikeda Y, Arnez JG, Finocchiaro G, Tanaka K. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta. 1990 May 16;1034(2):213–8. PubMed Europe PMC Scholia
  4. Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, Baillie TA. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact. 1994 Mar;90(3):253–75. PubMed Europe PMC Scholia
  5. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther. 1997 Nov;283(2):698–703. PubMed Europe PMC Scholia
  6. Ho PC, Abbott FS, Zanger UM, Chang TKH. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3(6):335–42. PubMed Europe PMC Scholia
  7. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340–6. PubMed Europe PMC Scholia
  8. Kiang TKL, Ho PC, Anari MR, Tong V, Abbott FS, Chang TKH. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006 Dec;94(2):261–71. PubMed Europe PMC Scholia
  9. Chung J-Y, Cho J-Y, Yu K-S, Kim J-R, Lim KS, Sohn D-R, et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595–600. PubMed Europe PMC Scholia
  10. Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229–36. PubMed Europe PMC Scholia
  11. Luís PBM, Ruiter JP, Ofman R, Ijlst L, Moedas M, Diogo L, et al. Valproic acid utilizes the isoleucine breakdown pathway for its complete β-oxidation. Biochem Pharmacol. 2011 Dec 1;82(11):1740–6. PubMed Europe PMC Scholia